Viatris anticipates the acquisitions adding $1 billion in sales by 2028, according to a Nov. 7 news release from the company. Oyster Point Pharma and Famy Life Sciences have an aggregate purchase price of $700 million to $750 million.
Viatris is aiming to close the Oyster Point acquisition in the first quarter of 2023, pending regulatory approval.
“Building on our success in the U.S. market, we are excited to join Viatris to now bring the strengths of Oyster Point to help build a leading global ophthalmology business,” Jeff Nau, PhD, CEO of Oyster Point, said in the release. “We believe that together we will meaningfully shape the future of eye care to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.